Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Q3 2025 earnings

Reported October 27, 2025 · After market close

Revenue$776.1MMiss by $47.3M
EPS$0.12Beat by $0.27
Revenue estimate$823.5M
EPS estimate-$0.15

Next report

Aug 3, 2026 (In 4 days)
Revenue estimate$932.0M
EPS estimate$0.96

Financials

Q3 2025

Income statement

See full
Revenue$776.1M+4.1%
Gross profit$636.0M+14.1%
Operating income-$46.7M-141%
Net income-$30.7M-129%
EPS (diluted)-$0.16-129%

Balance sheet

See full
Cash & equivalents$1.3B+85.1%
Total debt$600.0M0.0%
Total equity$6.1B+11.9%
Total assets$7.6B+11.1%

Cash flow

See full
Operating cash flow$368.7M+66.5%
CapEx$28.4M+54.1%
Free cash flow$340.2M+67.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$10.4B-22.3%
Enterprise value$9.75B-26.7%
P/E20×-21.5×
P/S3.4×-1.5×

Profitability

See full
Gross margin81.3%+2.5pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin26.9%—

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.1×0.0×
Current ratio4.8×+0.6×

Segments

By product

See full
VOXZOGO$218.4M+15.1%
VIMIZIM$182.8M+2.6%
NAGLAZYME$122.0M-7.5%
PALYNZIQ$108.8M+20.0%
ALDURAZYME$53.7M-24.4%

By segment

See full
Reportable Segment$776.1M+4.1%

Versus estimates

Revenue

Q1 2026$766.0MBeat by $13.5MQ4 2025$874.6MBeat by $40.8M
Q3 2025$776.1MMiss by $47.3M
Q2 2025$825.4MBeat by $63.5MQ1 2025$745.1MMiss by $17.3MQ4 2024$738.2MBeat by $25.9M

Diluted EPS

Q1 2026$0.55Miss by $0.39Q4 2025-$0.24Miss by $0.41
Q3 2025$0.12Beat by $0.27
Q2 2025$1.44Beat by $0.58Q1 2025$1.13Beat by $0.19Q4 2024$0.92Beat by $0.38

Ask the moment BioMarin Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BioMarin Pharmaceuticals report Q3 2025 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q3 2025 earnings on October 27, 2025 after market close.
What were BioMarin Pharmaceuticals's Q3 2025 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $776.1M and eps of $0.12 for Q3 2025.
Did BioMarin Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $823.5M by $47.3M. EPS beat the consensus estimate of $-0.15 by $0.27.
How did BioMarin Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.1% from $745.7M a year earlier and eps declined 86.8% from $0.91.
Where can I find BioMarin Pharmaceuticals's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001048477-25-000107) directly on SEC EDGAR. The filing index links above go to sec.gov.